Invesco Ltd. Biomarin Pharmaceutical Inc Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Invesco Ltd. holds 543,072 shares of BMRN stock, worth $36.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

543,072

Previous 537,450 1.05%

Holding current value

$36.2 Million

Previous $44.2 Million 13.73%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$69.02 - $93.84 $388,030 - $527,568	5,622 Added 1.05%	543,072 $38.2 Million
Q2 2024 Aug 13, 2024	BUY	$74.43 - $92.22 $9.19 Million - $11.4 Million	123,433 Added 29.81%	537,450 $44.2 Million
Q1 2024 May 14, 2024	BUY	$83.81 - $99.0 $1.5 Million - $1.77 Million	17,912 Added 4.52%	414,017 $36.2 Million
Q4 2023 Feb 12, 2024	SELL	$76.22 - $98.51 $4 Million - $5.17 Million	-52,512 Reduced 11.71%	396,105 $38.2 Million
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $45.6 Million - $50.6 Million	-535,553 Reduced 54.42%	448,617 $39.7 Million
Q2 2023 Aug 11, 2023	SELL	$86.68 - $100.3 $72.2 Million - $83.5 Million	-832,840 Reduced 45.84%	984,170 $85.3 Million
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $1.58 Million - $2.12 Million	-18,051 Reduced 0.98%	1,817,010 $177 Million
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $116 Million - $155 Million	1,430,955 Added 354.1%	1,835,061 $190 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $8.84 Million - $10.4 Million	107,568 Added 36.27%	404,106 $34.3 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $489,566 - $594,835	6,849 Added 2.36%	296,538 $24.6 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $465,438 - $580,795	6,266 Added 2.21%	289,689 $22.3 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $435,483 - $555,405	-6,072 Reduced 2.1%	283,423 $25 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $1.02 Million - $1.17 Million	13,676 Added 4.96%	289,495 $22.4 Million
Q2 2021 Aug 17, 2021	SELL	$75.51 - $84.79 $9.77 Million - $11 Million	-129,362 Reduced 31.93%	275,819 $23 Million
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $6.44 Million - $7.82 Million	86,222 Added 27.03%	405,181 $30.6 Million
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $19.4 Million - $24.1 Million	-267,701 Reduced 45.63%	318,959 $28 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $3.29 Million - $5.99 Million	45,748 Added 8.46%	586,660 $44.6 Million
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $1.02 Million - $1.59 Million	12,772 Added 2.42%	540,912 $66.7 Million
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $6.51 Million - $8.83 Million	-91,163 Reduced 14.72%	528,140 $44.6 Million
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $105 Million - $141 Million	-1,628,859 Reduced 72.45%	619,303 $52.4 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $40.3 Million - $50.9 Million	-597,674 Reduced 21.0%	2,248,162 $152 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $50 Million - $58.4 Million	-622,286 Reduced 17.94%	2,845,836 $244 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $12.9 Million - $15.1 Million	153,073 Added 4.62%	3,468,122 $308 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $266 Million - $352 Million	3,315,049 New	3,315,049 $282 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account